跳至主要内容
临床试验/NCT04025658
NCT04025658已完成不适用

Oxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With Twin Pregnancy

Samuel Lunenfeld Research Institute, Mount Sinai Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年8月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Uterine tone 2 minutes: questionnaire

研究概览

简要总结

Postpartum hemorrhage (PPH) due to uterine atony is a major cause of maternal morbidity and mortality. Uterotonic drugs are used to improve the muscle tone of the uterus after birth and these are effective at reducing the incidence of PPH. Large doses of this drug are associated with adverse effects like lower blood pressure, nausea, vomiting, abnormal heart rhythms and changes on ECG. Various international bodies recommend varying and high doses of oxytocin in elective cesarean sections. A study performed at Mount Sinai Hospital showed that a much smaller doses of oxytocin is required (ED95 being 0.35IU). Women who had twins were excluded from this study. It is known that women with a twin pregnancy have a higher risk of poor tone and postpartum hemorrhage.

The investigators seek to find the best dose of oxytocin for the patients with a twin pregnancy. A higher dose may be needed to contract the uterus adequately.

详细描述

Postpartum hemorrhage (PPH) is one of the leading causes of death during childbirth and accounts for an estimated 140,000 deaths per year worldwide. Furthermore, recent evidence has shown that the rate of PPH secondary to uterine atony is increasing.

Multiple pregnancy is a well-recognized risk factor for PPH. Compared with singleton pregnancy, women with a multiple pregnancy have an increased risk of PPH, severe PPH, transfusion, uterine atony, hysterectomy, prolonged hospital stay and death. This is true in both high- and low-income countries. Uterine atony as a cause of PPH is more likely in multiple pregnancy compared with singleton pregnancy.

Prophylactic uterotonic drugs administered after the delivery have been demonstrated to reduce the incidence of PPH by up to 40%. Oxytocin is the most commonly administered uterotonic drug used to prevent PPH in North America but is associated with adverse effects such as hypotension, nausea, vomiting, dysrhythmias, ST segment abnormalities, and severe water intoxication that may lead to pulmonary edema and convulsions.

Previous dose finding studies have excluded women with twin pregnancies. Therefore, the investigators wish to perform a double blinded dose finding study using the biased coin flip up-and-down sequential allocation technique to determine the ED 90 of oxytocin at cesarean section in those women with a twin pregnancy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Twin pregnancy
  • Elective cesarean delivery under regional anesthesia
  • Gestational age ≥36 weeks
  • No known additional risk factors for postpartum hemorrhage
  • Written informed consent to participate in this study

排除标准

  • Refusal to give written informed consent
  • Allergy or hypersensitivity to oxytocin
  • Conditions that may predispose to uterine atony and postpartum hemorrhage such as placenta previa, severe preeclampsia (as defined by SOGC guidelines (25)), polyhydramnios, uterine fibroids, previous history of uterine atony resulting in PPH, or bleeding diathesis and obesity, defined as pre-pregnancy BMI >40
  • Hepatic, renal, and vascular disease
  • Use of general anesthesia prior to the administration of the study drug

研究组 & 干预措施

Oxytocin 0.5IU

Active Comparator

Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.

干预措施: Oxytocin (Drug)

Oxytocin 1IU

Active Comparator

Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.

干预措施: Oxytocin (Drug)

Oxytocin 2IU

Active Comparator

Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.

干预措施: Oxytocin (Drug)

Oxytocin 3IU

Active Comparator

Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.

干预措施: Oxytocin (Drug)

Oxytocin 4IU

Active Comparator

Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.

干预措施: Oxytocin (Drug)

Oxytocin 5IU

Active Comparator

Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.

干预措施: Oxytocin (Drug)

结局指标

主要结局

Uterine tone 2 minutes: questionnaire

时间窗: 3 minutes

Uterine tone, defined as satisfactory or unsatisfactory by the obstetrician at 2 minutes after completion of the oxytocin injection (3 minutes post delivery).

次要结局

  • Presence of ventricular tachycardia: ECG(2 hours)
  • Need for uterine massage: questionnaire(20 minutes)
  • Intraoperative requirement for additional uterotonic medication(2 hours)
  • Tachycardia: heart rate greater than 130% of baseline(2 hours)
  • Presence of flushing: questionnaire(2 hours)
  • Intravenous fluid administered during surgery(2 hours)
  • Hypotension: systolic blood pressure less than 80% of baseline(2 hours)
  • Presence of atrial flutter: ECG(2 hours)
  • Calculated estimate of blood loss(24 hours)
  • Bradycardia: heart rate less than 70% of baseline(2 hours)
  • Presence of atrial fibrillation: ECG(2 hours)
  • Presence of vomiting: questionnaire(2 hours)
  • Presence of chest pain: questionnaire(2 hours)
  • Presence of shortness of breath: questionnaire(2 hours)
  • Presence of headache: questionnaire(2 hours)
  • Presence of nausea: questionnaire(2 hours)

研究者

发起方
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验